NBIX Biotechnology · Neurology · Rare disease · Commercial biotech · Thesis updated August 5, 2026

Three growth pillars, one ongoing legal overhang

INGREZZA remains the core driver, with management raising 2026 guidance to over $2.8 billion.
CRENESSITY is a proven second engine that exceeded $150 million in Q1 2026 sales.
The $2.9 billion Soleno deal adds VYKAT XR as a third commercial product.
Sales and marketing investments are high, meaning slow growth could hurt margins.
A DOJ investigation into INGREZZA sales practices remains a major unquantified risk.

01 Running thesis

Growth is real, risk is unresolved

Neurocrine successfully transitioned from a single-drug company into a diversified commercial biotech. The $2.9 billion acquisition of Soleno Therapeutics in May 2026 added VYKAT XR, creating a third revenue pillar alongside INGREZZA and CRENESSITY.

The bull case relies on sustained commercial momentum. INGREZZA continues to beat expectations, prompting a guidance raise to over $2.8 billion for 2026. CRENESSITY has launched well in rare diseases, and VYKAT XR adds another long-term growth engine before the pipeline matures in 2027.

The bear case centers on costs and legal risks. The company is spending heavily to support three commercial launches, which creates margin pressure if any product stalls. At the same time, a Department of Justice investigation into INGREZZA sales practices remains an unquantified overhang.

Jul 2026▲The Q2 2026 period confirmed the close of the $2.9 billion Soleno acquisition, adding VYKAT XR. INGREZZA guidance was raised, while the DOJ investigation remained an overhang.

May 2026→Q1 2026 confirmed the current story. INGREZZA and CRENESSITY kept growing, the Soleno deal was on track, and there was no new detail on the DOJ investigation.

Feb 2026▲CRENESSITY's first full year showed blockbuster potential, reducing reliance on INGREZZA. The offset was higher planned SG&A spending to support both sales forces.

Oct 2025→CRENESSITY sales jumped, and management chose to spend more on sales expansion. The new DOJ investigation into INGREZZA marketing added a serious overhang.

Jul 2025▲CRENESSITY sales more than tripled from Q1 to Q2 2025. INGREZZA guidance was narrowed as payer pricing pressure became more visible.

May 2025▲INGREZZA posted record new patient starts, and CRENESSITY showed an encouraging first full quarter of launch. These data points supported the move toward a multi-product business.

Feb 2025→Crinecerfont approval moved Neurocrine beyond a single-product setup. INGREZZA guidance also pointed to slower growth, raising the bar for commercial execution.

02 Business model

Specialty drugs, heavy sales effort

Neurocrine makes money by selling specialized branded medicines. INGREZZA treats tardive dyskinesia, CRENESSITY treats congenital adrenal hyperplasia, and VYKAT XR treats hyperphagia in Prader-Willi syndrome.

The company operates a heavy commercial model. It spends significant capital on sales teams, patient support, and market access. This drives top-line growth but raises fixed costs.

The primary vulnerability is operating leverage. If INGREZZA volume slows, or if VYKAT XR integration struggles, the high sales and administrative expenses will compress earnings. Management is betting that aggressive market development will outrun these costs.

03 Product portfolio

Products that carry the story

Cash cow

INGREZZA

The flagship product for tardive dyskinesia and Huntington's disease chorea, expected to clear $2.8 billion in 2026 sales.

Growth engine

CRENESSITY

A treatment for congenital adrenal hyperplasia that reached $153 million in Q1 2026 sales.

Growth engine

VYKAT XR

Acquired via the Soleno deal in May 2026, this is the only approved treatment for hyperphagia in Prader-Willi syndrome.

Option

Osuvampator

A late-stage asset in Phase III testing for major depressive disorder, with data expected in 2027.

Option

Direclidine

A Phase III asset for schizophrenia, also expecting top-line results in 2027.

04 Business segments

Q1 sales mix is still INGREZZA-led

INGREZZA81%modest

CRENESSITY19%growing fast

The mix reflects Q1 2026 net product sales of $811 million, with INGREZZA at $657 million and CRENESSITY at $153 million. VYKAT XR was acquired in Q2 and will alter future mixes.

05 Risk factors

What could break the thesis

DOJ investigation

High impact · Medium odds

In 2025, Neurocrine received a Civil Investigative Demand from the Department of Justice regarding INGREZZA sales and marketing. The outcome is unknown and could result in fines or limits on sales practices.

We watchAny reserve accrual or settlement update in quarterly filings.

M&A integration

Medium impact · Medium odds

The $2.9 billion Soleno acquisition brings VYKAT XR, but rare disease launches require precise execution. If the commercial rollout falters, the deal will fail to generate expected returns.

We watchSequential VYKAT XR sales growth in late 2026.

Sales spending outruns growth

High impact · Medium odds

The company is funding three commercial launches simultaneously. If INGREZZA slows or CRENESSITY stalls, these high fixed costs will squeeze profits.

We watchQuarterly SG&A growth compared to net product sales growth.

2027 pipeline misses

Medium impact · Medium odds

Osuvampator and direclidine represent the next growth wave. Both face critical Phase III readouts in 2027. Trial failures would cut future optionality.

We watchPhase III top-line results for both assets.

06 Quick answers

In one breath

What does Neurocrine Biosciences sell?

Neurocrine sells branded medicines for neurological, endocrine, and psychiatric disorders. Its biggest product is INGREZZA, and its newer growth products are CRENESSITY and VYKAT XR.

Why does INGREZZA matter so much to NBIX?

INGREZZA produced $657 million of Q1 2026 sales, making it the main driver of the company. That scale funds sales investments, acquisitions, and pipeline work.

What is the main risk for NBIX stock?

The biggest specific risk is the DOJ investigation into INGREZZA sales and marketing. The other key risk is that the company is spending more on sales teams, so any slowdown in product growth could hurt margins.

When could the pipeline matter?

The next major pipeline moments are expected in 2027. Neurocrine expects top-line Phase III results for osuvampator in major depressive disorder and direclidine in schizophrenia.